ClinicalTrials.gg
Not yet recruitingNCT07785193Updated Aug 26, 2026

A Study of Subcutaneous FL115 Monotherapy in Participants With Advanced Solid Tumors

A Phase 1 interventional study of FL115 in Advanced Solid Tumours, sponsored by Suzhou Forlong Biotechnology Co., Ltd. Not yet recruiting at 1 site in Australia. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by Suzhou Forlong Biotechnology Co., Ltd · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
29
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This is an open-label, multicenter, dose-escalation Phase Ib clinical study to evaluate the safety, tolerability, efficacy, PK, and PD of FL115 injection administered subcutaneously as monotherapy in participants with advanced solid tumours. All enrolled participants will receive FL115 by subcutaneous injection. Each treatment cycle comprises 21 days, with administration once every 3 weeks (Q3W). Treatment will continue until initiation of new anti-tumour therapy, progressive disease (PD), unacceptable toxicity, death, withdrawal of informed consent, loss to follow-up, or study termination by the Sponsor, whichever occurs first.

02

Conditions studied

  • Advanced Solid Tumours
03

In context

Lead sponsor

Suzhou Forlong Biotechnology Co., Ltd is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants aged ≥18 and ≤80 years.
  2. Able to understand and willing to sign the Participant Information and Consent Form (PICF).
  3. Participants with or cytologically confirmed locally advanced unresectable and/or solid tumours who have disease progression after standard therapy, are intolerant to standard therapy, or for whom no standard therapy is available.
  4. The participant must have received and progressed on (CPIs).
  5. At least 4 weeks since prior major surgery and recovered from its effects (per investigator judgment).
  6. With at least one (according to v1.1).
  7. score: 0 - 1.
  8. ≥12 weeks (as judged by the investigator).
  9. Adequate organ function.
  10. Fertile subjects (male and female) and their partners agree to use acceptable, investigator-approved during the study-required period.

Exclusion criteria

Exclusion Criteria:

  1. Prior Anti-tumour Therapy:

    1. Prior treatment with IL-2/IL-15 agonists;
    2. Prior anti-tumour therapy without completion of the required before first dose;
    3. Participants who have previously received extensive radiotherapy;
    4. Prior treatment with 3 or more lines of (CPIs).
  2. Other Prior Therapies and Recovery from Toxicities:

    1. Known or suspected allergy to FL115 or its ;
    2. Systemic immunomodulatory therapy within 4 weeks before first dose, except: hormone doses of ≤10 mg/day prednisone equivalent; topical, inhaled, or intranasal ; prophylactic single use of corticosteroids before contrast-enhanced imaging for participants with contrast media allergy;
    3. History of allogeneic organ transplant or allogeneic peripheral blood stem cell (PBSC)/bone marrow transplant;
    4. Receipt of a within 4 weeks prior to the first dose of the product;
    5. Prior Grade ≥3 irAEs or irAEs leading to discontinuation of immunotherapy;
    6. AEs from prior anti-tumour therapy not recovered to baseline or Grade ≤1 ( v5.0) before first dose. Exceptions: alopecia (any grade), peripheral sensory neuropathy (≤Grade 2), hypothyroidism controlled with HRT, or other conditions specified as permissible in the inclusion/exclusion criteria may be enrolled; other AEs (≤Grade 2) approved by the investigator and Sponsor medical monitor.
  3. Prior Medical and Surgical History:

    1. Participants with to meninges, or symptomatic , or brain metastasis that has been stable for less than 4 weeks after treatment prior to the first dose , or with spinal cord compression or carcinomatous meningitis;
    2. Participants with other malignant diseases within 2 years prior to screening tests, other than the disease under study. Participants with curable local tumours (e.g., basal or squamous cell skin cancer, cervical or breast cancer in situ) may be enrolled after definitive cure;
    3. Active disease or a known history of autoimmune disease requiring systemic hormones or ;
    4. Participants with a history of any of the following pulmonary toxicities:

      1. severe lung-specific diseases;
      2. Active interstitial lung disease (ILD) or interstitial pneumonitis; history of ILD or (non-infectious) pneumonitis requiring treatment with corticosteroids or other immunosuppressants;
      3. Active pulmonary tuberculosis infection within 1 year prior to enrolment, or a history of active pulmonary tuberculosis infection more than 1 year ago without standard treatment, as identified by medical history.
    5. Uncontrolled pleural effusion, pericardial effusion, or ascites as judged by the investigator ;
    6. History of clinically significant cardiovascular disorder;
    7. corrected for heart rate (QTcF) prolongation at baseline, defined as an average of three consecutive measurements during screening of >470 ms for females and >450 ms for males, or a history of long QT syndrome ;
    8. Hepatic cirrhosis of Class B or worse; or any degree of hepatic cirrhosis with a history of hepatic encephalopathy.
  4. History of Infectious Diseases:

    1. Severe infection within 4 weeks prior to the first dose;
    2. Any confirmed active , or infection.
  5. Other Conditions:

    1. Pregnant or breastfeeding women;
    2. Known, documented, or suspected drug abuse;
    3. In the investigator's opinion, the participant is unsuitable for participation in this study for other reasons.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
29 participants (estimated)

Study arms

  • Experimental
    A Single Arm

    Drug: FL115

Interventions

  • DrugFL115

    FL115 is a novel long-acting IL-15 agonist designed as a fusion protein with a mutated IL-15 structure (IL-15\[N72D\]/IL-15Rα-sFc).

06

What researchers measure

Primary outcomes

  1. Incidence of TEAEs and SAEs

    All treatment-emergent adverse events and serious adverse events are recorded and graded using the NCI Common Terminology Criteria for Adverse Events version 5.0.

    Time frame: TEAEs: From first dose to 30 days after the last dose or initiation of new anti-tumour therapy, whichever occurs first. SAEs: From PICF signing through the TEAE collection period; thereafter, only treatment- or study-related SAEs will be collected.

  2. MTD and RP2D

    Maximum tolerated dose, Recommended Phase 2 dose

    Time frame: through study completion, an average of 15 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2026
First posted
Aug 25, 2026
StartEst.
Sep 2026
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2029
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07785193
Lead sponsor
Suzhou Forlong Biotechnology Co., Ltd
Collaborators
Novotech (Australia) Pty Limited
Responsible party
Sponsor
First posted
Aug 25, 2026
Start date
Sep 2026 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Sep 2029 (estimated)
Last update
Aug 26, 2026

Study contacts

Xiajun Xu
Contact
xiajunxu@forlongbiotech.com
+86-18101882657

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IL-15(N72D)/IL-15Ralpha-sFc Fusion Protein Complex FL115

Start the discussion